<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960830</url>
  </required_header>
  <id_info>
    <org_study_id>PS990</org_study_id>
    <nct_id>NCT00960830</nct_id>
  </id_info>
  <brief_title>Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety</brief_title>
  <official_title>Mirtazapine Reduces ICD Appropriate Shocks in Cardioverter Implanted Patients With Depression and Anxiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Nacional de Rosario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Nacional de Rosario</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the use of antidepressant medication in depressed
      patients with implantable cardioverter defibrillator reduces the number of ICD's shocks as it
      improves depressive affect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      episodes of arrhythmia remain present even after icd implantation, this is specially true in
      depressed patients. it is hypothesized that improving mood state by means of an
      antidepressant drug . namely mirtazapine. could be responsible of alleviating the number of
      appropriate shocks delivered by the cardioverter. this could be due to a direct effect of the
      drug itself or an indirect effect of improving anxious and depressive affect. the mood and
      anxiety state are measured with the HADS scale
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of implantable cardioverter defibrillator shocks</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of depression</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>mirtazapine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mirtazapine, sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirtazapine</intervention_name>
    <description>mirtazapine 15 mg daily tablets</description>
    <arm_group_label>mirtazapine</arm_group_label>
    <other_name>mirtazapine 1500 mtz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirtazapine</intervention_name>
    <description>15 mg daily</description>
    <arm_group_label>mirtazapine</arm_group_label>
    <arm_group_label>mirtazapine, sugar pill</arm_group_label>
    <other_name>remeron 1569 rem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cardioverter implanted patients

          -  depression

          -  anxiety

        Exclusion Criteria:

          -  heart failure

          -  other diseases reducing physical fitness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>daniel jl serrani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>facultad de psicologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cl Sn Nicol</name>
      <address>
        <city>San Nicolas</city>
        <state>Bs As</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>August 17, 2009</last_update_submitted>
  <last_update_submitted_qc>August 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>daniel serrani</name_title>
    <organization>facultad de psicologia</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

